Claudins overexpression in ovarian cancer: Potential targets for clostridium perfringens enterotoxin (CPE) based diagnosis and therapy

International Journal of Molecular Sciences

Volumn 14, Issue 5, 2013, Pages 10412-10437

  English, Diana P ^a   Santin, Alessandro D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Claudin; Clostridium perfringens enterotoxin; Immuno therapy; Ovarian cancer; Tight junction

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CLAUDIN; CLAUDIN 3; CLAUDIN 4; CLAUDIN 5; CLAUDIN 7; CLOSTRIDIUM PERFRINGENS ENTEROTOXIN; ENTEROTOXIN; PACLITAXEL; UNCLASSIFIED DRUG; ENTEROTOXIN, CLOSTRIDIUM;

ABSENCE OF SIDE EFFECTS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG CYTOTOXICITY; DRUG MECHANISM; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; OVARY CANCER; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TUMOR INVASION; ANIMAL; FEMALE; GENE THERAPY; GENETICS; METABOLISM; OVARIAN NEOPLASMS; PROCEDURES;

ANIMALS; CLAUDIN-3; CLAUDIN-4; CLAUDINS; ENTEROTOXINS; FEMALE; GENETIC THERAPY; HUMANS; OVARIAN NEOPLASMS;

EID: 84878262797     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms140510412     Document Type: Review

References (152)

1. Soini, Y.; Talvensaari-Mattila, A. Expression of claudins 1, 4, 5, and 7 in ovarian tumors of diverse types. Int. J. Gynecol. Pathol. 2006, 25, 330-335.
2. Tsukita, S.; Furuse, M.; Itoh, M. Multifunctional strands in tight junctions. Nat. Rev. Mol. Cell Biol. 2001, 2, 285-293.
3. Furuse, M.; Fujita, K.; Hiiragi, T.; Fujimoto, K.; Tsukita, S. Claudin-1 and -2: Novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J. Cell Biol. 1998, 141, 1539-1550.
4. Furuse, M.; Hirase, T.; Itoh, M.; Nagafuchi, A.; Yonemura, S.; Tsukita, S. Occludin: A novel integral membrane protein localizing at tight junctions. J. Cell Biol. 1993, 123, 1777-1788.
5. Swift, J.G.; Mukherjee, T.M.; Rowland, R. Intercellular junctions in hepatocellular carcinoma. J. Submicrosc. Cytol. 1983, 15, 799-810.
6. Furuse, M.; Sasaki, H.; Fujimoto, K.; Tsukita, S. A single gene product, claudin-1 or -2, reconstitutes tight junction strands and recruits occludin in fibroblasts. J. Cell Biol. 1998, 143, 391-401.
7. Tsukita, S.; Furuse, M. Pores in the wall: Claudins constitute tight junction strands containing aqueous pores. J. Cell Biol. 2000, 149, 13-16.
8. Martin, T.A.; Watkins, G.; Mansel, R.E.; Jiang, W.G. Loss of tight junction plaque molecules in breast cancer tissues is associated with a poor prognosis in patients with breast cancer. Eur. J. Cancer 2004, 40, 2717-2725.
9. Mitic, L.L.; Anderson, J.M. Molecular architecture of tight junctions. Annu. Rev. Physiol. 1998, 60, 121-142.
10. Morin, P.J. Claudin proteins in human cancer: Promising new targets for diagnosis and therapy. Cancer Res. 2005, 65, 9603-9606.
11. Turksen, K.; Troy, T.C. Barriers built on claudins. J. Cell Sci. 2004, 117, 2435-2447.
12. Chen, Y.; Lu, Q.; Schneeberger, E.E.; Goodenough, D.A. Restoration of tight junction structure and barrier function by down-regulation of the mitogen-activated protein kinase pathway in ras-transformed madin-darby canine kidney cells. Mol. Biol. Cell 2000, 11, 849-862.
13. Singh, A.B.; Sharma, A.; Dhawan, P. Claudin family of proteins and cancer: An overview. J. Oncol. 2010, 2010, 541957.
14. Rangel, L.B.; Agarwal, R.; D'Souza, T.; Pizer, E.S.; Alo, P.L.; Lancaster, W.D.; Gregoire, L.; Schwartz, D.R.; Cho, K.R.; Morin, P.J. Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin. Cancer Res. 2003, 9, 2567-2575.
15. Bignotti, E.; Tassi, R.A.; Calza, S.; Ravaggi, A.; Romani, C.; Rossi, E.; Falchetti, M.; Odicino, F.E.; Pecorelli, S.; Santin, A.D. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: Identification of novel molecular biomarkers for early diagnosis and therapy. Gynecol. Oncol. 2006, 103, 405-416.
16. Hough, C.D.; Sherman-Baust, C.A.; Pizer, E.S.; Montz, F.J.; Im, D.D.; Rosenshein, N.B.; Cho, K.R.; Riggins, G.J.; Morin, P.J. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res. 2000, 60, 6281-6287.
17. Rangel, L.B.; Sherman-Baust, C.A.; Wernyj, R.P.; Schwartz, D.R.; Cho, K.R.; Morin, P.J. Characterization of novel human ovarian cancer-specific transcripts (hosts) identified by serial analysis of gene expression. Oncogene 2003, 22, 7225-7232.
18. Santin, A.D.; Zhan, F.; Bellone, S.; Palmieri, M.; Cane, S.; Bignotti, E.; Anfossi, S.; Gokden, M.; Dunn, D.; Roman, J.J.; et al. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: Identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int. J. Cancer 2004, 112, 14-25.
19. Ismail, R.S.; Baldwin, R.L.; Fang, J.; Browning, D.; Karlan, B.Y.; Gasson, J.C.; Chang, D.D. Differential gene expression between normal and tumor-derived ovarian epithelial cells. Cancer Res. 2000, 60, 6744-6749.
20. Welsh, J.B.; Zarrinkar, P.P.; Sapinoso, L.M.; Kern, S.G.; Behling, C.A.; Monk, B.J.; Lockhart, D.J.; Burger, R.A.; Hampton, G.M. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc. Natl. Acad. Sci. USA 2001, 98, 1176-1181.
21. Schwartz, D.R.; Kardia, S.L.; Shedden, K.A.; Kuick, R.; Michailidis, G.; Taylor, J.M.; Misek, D.E.; Wu, R.; Zhai, Y.; Darrah, D.M.; et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res. 2002, 62, 4722-4729.
22. Ono, K.; Tanaka, T.; Tsunoda, T.; Kitahara, O.; Kihara, C.; Okamoto, A.; Ochiai, K.; Takagi, T.; Nakamura, Y. Identification by cdna microarray of genes involved in ovarian carcinogenesis. Cancer Res. 2000, 60, 5007-5011.
23. Shridhar, V.; Lee, J.; Pandita, A.; Iturria, S.; Avula, R.; Staub, J.; Morrissey, M.; Calhoun, E.; Sen, A.; Kalli, K.; et al. Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res. 2001, 61, 5895-5904.
24. Hough, C.D.; Cho, K.R.; Zonderman, A.B.; Schwartz, D.R.; Morin, P.J. Coordinately up-regulated genes in ovarian cancer. Cancer Res. 2001, 61, 3869-3876.
25. Shridhar, V.; Sen, A.; Chien, J.; Staub, J.; Avula, R.; Kovats, S.; Lee, J.; Lillie, J.; Smith, D.I. Identification of underexpressed genes in early- and late-stage primary ovarian tumors by suppression subtraction hybridization. Cancer Res. 2002, 62, 262-270.
26. Jazaeri, A.A.; Lu, K.; Schmandt, R.; Harris, C.P.; Rao, P.H.; Sotiriou, C.; Chandramouli, G.V.; Gershenson, D.M.; Liu, E.T. Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Mol. Carcinog. 2003, 36, 53-59.
27. Soini, Y. Expression of claudins 1, 2, 3, 4, 5 and 7 in various types of tumours. Histopathology 2005, 46, 551-560.
28. Kleinberg, L.; Holth, A.; Trope, C.G.; Reich, R.; Davidson, B. Claudin upregulation in ovarian carcinoma effusions is associated with poor survival. Human Pathol. 2008, 39, 747-757.
29. Resnick, M.B.; Konkin, T.; Routhier, J.; Sabo, E.; Pricolo, V.E. Claudin-1 is a strong prognostic indicator in stage ii colonic cancer: A tissue microarray study. Mod. Pathol. 2005, 18, 511-518.
30. Sanada, Y.; Oue, N.; Mitani, Y.; Yoshida, K.; Nakayama, H.; Yasui, W. Down-regulation of the claudin-18 gene, identified through serial analysis of gene expression data analysis, in gastric cancer with an intestinal phenotype. J. Pathol. 2006, 208, 633-642.
31. Cheung, S.T.; Leung, K.L.; Ip, Y.C.; Chen, X.; Fong, D.Y.; Ng, I.O.; Fan, S.T.; So, S. Claudin-10 expression level is associated with recurrence of primary hepatocellular carcinoma. Clin. Cancer Res. 2005, 11, 551-556.
32. Gonzalez-Mariscal, L.; Betanzos, A.; Nava, P.; Jaramillo, B.E. Tight junction proteins. Prog. Biophys. Mol. Biol. 2003, 81, 1-44.
33. Van Itallie, C.M.; Anderson, J.M. Claudins and epithelial paracellular transport. Annu. Rev. Physiol. 2006, 68, 403-429.
34. Lal-Nag, M.; Morin, P.J. The claudins. Genome Biol. 2009, 10, 235.
35. Morita, K.; Furuse, M.; Fujimoto, K.; Tsukita, S. Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. Proc. Natl. Acad. Sci. USA 1999, 96, 511-516.
36. Ikenouchi, J.; Furuse, M.; Furuse, K.; Sasaki, H.; Tsukita, S. Tricellulin constitutes a novel barrier at tricellular contacts of epithelial cells. J. Cell Biol. 2005, 171, 939-945.
37. Steed, E.; Rodrigues, N.T.; Balda, M.S.; Matter, K. Identification of marveld3 as a tight junction-associated transmembrane protein of the occludin family. BMC Cell Biol. 2009, 10, 95.
38. Krause, G.; Winkler, L.; Mueller, S.L.; Haseloff, R.F.; Piontek, J.; Blasig, I.E. Structure and function of claudins. Biochim. Biophys. Acta 2008, 1778, 631-645.
39. Umeda, K.; Ikenouchi, J.; Katahira-Tayama, S.; Furuse, K.; Sasaki, H.; Nakayama, M.; Matsui, T.; Tsukita, S.; Furuse, M. Zo-1 and zo-2 independently determine where claudins are polymerized in tight-junction strand formation. Cell 2006, 126, 741-754.
40. D'Souza, T.; Agarwal, R.; Morin, P.J. Phosphorylation of claudin-3 at threonine 192 by camp-dependent protein kinase regulates tight junction barrier function in ovarian cancer cells. J. Biol. Chem. 2005, 280, 26233-26240.
41. Hewitt, K.J.; Agarwal, R.; Morin, P.J. The claudin gene family: Expression in normal and neoplastic tissues. BMC Cancer 2006, 6, 186.
42. Shang, X.; Lin, X.; Alvarez, E.; Manorek, G.; Howell, S.B. Tight junction proteins claudin-3 and claudin-4 control tumor growth and metastases. Neoplasia 2012, 14, 974-985.
43. Hibbs, K.; Skubitz, K.M.; Pambuccian, S.E.; Casey, R.C.; Burleson, K.M.; Oegema, T.R., Jr.; Thiele, J.J.; Grindle, S.M.; Bliss, R.L.; Skubitz, A.P. Differential gene expression in ovarian carcinoma: Identification of potential biomarkers. Am. J. Pathol. 2004, 165, 397-414.
44. Daugherty, B.L.; Ward, C.; Smith, T.; Ritzenthaler, J.D.; Koval, M. Regulation of heterotypic claudin compatibility. J. Biol. Chem. 2007, 282, 30005-30013.
45. Piontek, J.; Winkler, L.; Wolburg, H.; Muller, S.L.; Zuleger, N.; Piehl, C.; Wiesner, B.; Krause, G.; Blasig, I.E. Formation of tight junction: Determinants of homophilic interaction between classic claudins. FASEB J. 2008, 22, 146-158.
46. Piehl, C.; Piontek, J.; Cording, J.; Wolburg, H.; Blasig, I.E. Participation of the second extracellular loop of claudin-5 in paracellular tightening against ions, small and large molecules. Cell Mol. Life Sci. 2010, 67, 2131-2140.
47. Huber, J.D.; Witt, K.A.; Hom, S.; Egleton, R.D.; Mark, K.S.; Davis, T.P., Inflammatory pain alters blood-brain barrier permeability and tight junctional protein expression. Am. J. Physiol. Heart Circ. Physiol. 2001, 280, H1241-H1248.
48. Sawada, N.; Murata, M.; Kikuchi, K.; Osanai, M.; Tobioka, H.; Kojima, T.; Chiba, H. Tight junctions and human diseases. Med. Electron. Microsc. 2003, 36, 147-156.
49. Wolburg, H.; Wolburg-Buchholz, K.; Liebner, S.; Engelhardt, B. Claudin-1, claudin-2 and claudin-11 are present in tight junctions of choroid plexus epithelium of the mouse. Neurosci. Lett. 2001, 307, 77-80.
50. Bronstein, J.M.; Tiwari-Woodruff, S.; Buznikov, A.G.; Stevens, D.B. Involvement of osp/claudin-11 in oligodendrocyte membrane interactions: Role in biology and disease. J. Neurosci. Res. 2000, 59, 706-711.
51. Wilcox, E.R.; Burton, Q.L.; Naz, S.; Riazuddin, S.; Smith, T.N.; Ploplis, B.; Belyantseva, I.; Ben-Yosef, T.; Liburd, N.A.; Morell, R.J., et al. Mutations in the gene encoding tight junction claudin-14 cause autosomal recessive deafness dfnb29. Cell 2001, 104, 165-172.
52. Gye, M.C. Changes in the expression of claudins and transepithelial electrical resistance of mouse sertoli cells by leydig cell coculture. Int. J. Androl. 2003, 26, 271-278.
53. Swisshelm, K.; Macek, R.; Kubbies, M. Role of claudins in tumorigenesis. Adv. Drug Deliv. Rev. 2005, 57, 919-928.
54. Lu, K.H.; Patterson, A.P.; Wang, L.; Marquez, R.T.; Atkinson, E.N.; Baggerly, K.A.; Ramoth, L.R.; Rosen, D.G.; Liu, J.; Hellstrom, I.; et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin. Cancer Res. 2004, 10, 3291-3300.
55. Zhu, Y.; Brannstrom, M.; Janson, P.O.; Sundfeldt, K. Differences in expression patterns of the tight junction proteins,claudin 1, 3, 4 and 5, in human ovarian surface epithelium as compared to epithelia in inclusion cysts and epithelial ovarian tumours. Int. J. Cancer 2006, 118, 1884-1891.
56. Heinzelmann-Schwarz, V.A.; Gardiner-Garden, M.; Henshall, S.M.; Scurry, J.; Scolyer, R.A.; Davies, M.J.; Heinzelmann, M.; Kalish, L.H.; Bali, A.; Kench, J.G.; et al. Overexpression of the cell adhesion molecules ddr1, claudin 3, and ep-cam in metaplastic ovarian epithelium and ovarian cancer. Clin. Cancer Res. 2004, 10, 4427-4436.
57. Kominsky, S.L.; Argani, P.; Korz, D.; Evron, E.; Raman, V.; Garrett, E.; Rein, A.; Sauter, G.; Kallioniemi, O.P.; Sukumar, S. Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene 2003, 22, 2021-2033.
58. Johnson, A.H.; Frierson, H.F.; Zaika, A.; Powell, S.M.; Roche, J.; Crowe, S.; Moskaluk, C.A.; El-Rifai, W. Expression of tight-junction protein claudin-7 is an early event in gastric tumorigenesis. Am. J. Pathol. 2005, 167, 577-584.
59. Agarwal, R.; D'Souza, T.; Morin, P.J. Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. Cancer Res. 2005, 65, 7378-7385.
60. Higashi, Y.; Suzuki, S.; Sakaguchi, T.; Nakamura, T.; Baba, S.; Reinecker, H.C.; Nakamura, S.; Konno, H. Loss of claudin-1 expression correlates with malignancy of hepatocellular carcinoma. J. Surg. Res. 2007, 139, 68-76.
61. Hadj-Rabia, S.; Baala, L.; Vabres, P.; Hamel-Teillac, D.; Jacquemin, E.; Fabre, M.; Lyonnet, S.; De Prost, Y.; Munnich, A.; Hadchouel, M.; et al. Claudin-1 gene mutations in neonatal sclerosing cholangitis associated with ichthyosis: A tight junction disease. Gastroenterology 2004, 127, 1386-1390.
62. Lameris, A.L.; Huybers, S.; Burke, J.R.; Monnens, L.A.; Bindels, R.J.; Hoenderop, J.G. Involvement of claudin 3 and claudin 4 in idiopathic infantile hypercalcaemia: A novel hypothesis? Nephrol. Dial. Transplant. 2010, 25, 3504-3509.
63. Morita, K.; Sasaki, H.; Furuse, M.; Tsukita, S. Endothelial claudin: Claudin-5/tmvcf constitutes tight junction strands in endothelial cells. J. Cell Biol. 1999, 147, 185-194.
64. Gonzalez-Mariscal, L.; Tapia, R.; Chamorro, D. Crosstalk of tight junction components with signaling pathways. Biochim. Biophys. Acta 2008, 1778, 729-756.
65. Matsuda, M.; Kubo, A.; Furuse, M.; Tsukita, S. A peculiar internalization of claudins, tight junction-specific adhesion molecules, during the intercellular movement of epithelial cells. J. Cell Sci. 2004, 117, 1247-1257.
66. Ikenouchi, J.; Matsuda, M.; Furuse, M.; Tsukita, S. Regulation of tight junctions during the epithelium-mesenchyme transition: Direct repression of the gene expression of claudins/occludin by snail. J. Cell Sci. 2003, 116, 1959-1967.
67. Escaffit, F.; Boudreau, F.; Beaulieu, J.F. Differential expression of claudin-2 along the human intestine: Implication of gata-4 in the maintenance of claudin-2 in differentiating cells. J. Cell. Physiol. 2005, 203, 15-26.
68. Singh, A.B.; Harris, R.C. Epidermal growth factor receptor activation differentially regulates claudin expression and enhances transepithelial resistance in madin-darby canine kidney cells. J. Biol. Chem. 2004, 279, 3543-3552.
69. Grande, M.; Franzen, A.; Karlsson, J.O.; Ericson, L.E.; Heldin, N.E.; Nilsson, M. Transforming growth factor-beta and epidermal growth factor synergistically stimulate epithelial to mesenchymal transition (emt) through a mek-dependent mechanism in primary cultured pig thyrocytes. J. Cell Sci. 2002, 115, 4227-4236.
70. Flores-Benitez, D.; Ruiz-Cabrera, A.; Flores-Maldonado, C.; Shoshani, L.; Cereijido, M.; Contreras, R.G. Control of tight junctional sealing: Role of epidermal growth factor. Am. J. Physiol. Renal. Physiol. 2007, 292, F828-F836.
71. Ogawa, M.; Kojima, T.; Someya, M.; Nomura, K.; Takasawa, A.; Murata, M.; Tanaka, S.; Saito, T.; Sawada, N. Epidermal growth factor modulates claudins and tight junctional functions in ovarian cancer cell lines. Histochem. Cell Biol. 2012, 138, 323-338.
72. Zhu, Y.; Sundfeldt, K. Tight junction formation in epithelial ovarian adenocarcinoma. Acta Obstet. Gynecol. Scand. 2007, 86, 1011-1019.
73. Qin, W.; Ren, Q.; Liu, T.; Huang, Y.; Wang, J. Microrna-155 is a novel suppressor of ovarian cancer-initiating cells that targets cldn1. FEBS Lett. 2013, 587, 1434-1439.
74. laSuh, Y.; Yoon, C.H.; Kim, R.K.; Lim, E.J.; Oh, Y.S.; Hwang, S.G.; An, S.; Yoon, G.; Gye, M.C.; Yi, J.M.; et al. Claudin-1 induces epithelial-mesenchymal transition through activation of the c-abl-erk signaling pathway in human liver cells. Oncogene 2012, doi:10.1038/onc.2012.505.
75. Liu, T.; Cheng, W.; Lai, D.; Huang, Y.; Guo, L. Characterization of primary ovarian cancer cells in different culture systems. Oncol. Rep. 2010, 23, 1277-1284.
76. Soini, Y. Claudins 2, 3, 4, and 5 in paget's disease and breast carcinoma. Human Pathol. 2004, 35, 1531-1536.
77. Patonai, A.; Erdelyi-Belle, B.; Korompay, A.; Somoracz, A.; Straub, B.K.; Schirmacher, P.; Kovalszky, I.; Lotz, G.; Kiss, A.; Schaff, Z. Claudins and tricellulin in fibrolamellar hepatocellular carcinoma. Virchows Archiv. 2011, 458, 679-688.
78. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M.J. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59, 225-249.
79. Bristow, R.E.; Tomacruz, R.S.; Armstrong, D.K.; Trimble, E.L.; Montz, F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J. Clin. Oncol. 2002, 20, 1248-1259.
80. Monk, B.J.; Coleman, R.L. Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: From platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds. Int. J. Gynecol. Cancer 2009, 19, S63-S67.
81. Boylan, K.L.; Misemer, B.; Derycke, M.S.; Andersen, J.D.; Harrington, K.M.; Kalloger, S.E.; Gilks, C.B.; Pambuccian, S.E.; Skubitz, A.P. Claudin 4 is differentially expressed between ovarian cancer subtypes and plays a role in spheroid formation. Int. J. Mol. Sci. 2011, 12, 1334-1358.
82. Li, J.; Chigurupati, S.; Agarwal, R.; Mughal, M.R.; Mattson, M.P.; Becker, K.G.; Wood, W.H., 3rd; Zhang, Y.; Morin, P.J. Possible angiogenic roles for claudin-4 in ovarian cancer. Cancer Biol. Ther. 2009, 8, 1806-1814.
83. Bellone, S.; Betti, M.; English, D.; Cocco, E.; Gasparrini, S.; Bortolomai, I.; Todeschini, P.; Romani, C.; Ravaggi, A.; Bignotti, E.; et al. Mammaglobin b (scgb2a1) is a novel tumor rejection antigen and highly differentially expressed gene in all major histological types of ovarian cancer. Br. J. Cancer 2013, submitted for publication.
84. Banz, C.; Ungethuem, U.; Kuban, R.J.; Diedrich, K.; Lengyel, E.; Hornung, D. The molecular signature of endometriosis-associated endometrioid ovarian cancer differs significantly from endometriosis-independent endometrioid ovarian cancer. Fertil. Steril. 2010, 94, 1212-1217.
85. Tassi, R.A.; Bignotti, E.; Falchetti, M.; Ravanini, M.; Calza, S.; Ravaggi, A.; Bandiera, E.; Facchetti, F.; Pecorelli, S.; Santin, A.D. Claudin-7 expression in human epithelial ovarian cancer. Int. J. Gynecol. Cancer 2008, 18, 1262-1271.
86. Dahiya, N.; Becker, K.G.; Wood, W.H., 3rd; Zhang, Y.; Morin, P.J. Claudin-7 is frequently overexpressed in ovarian cancer and promotes invasion. PLoS One 2011, 6, e22119.
87. Szabo, I.; Kiss, A.; Schaff, Z.; Sobel, G. Claudins as diagnostic and prognostic markers in gynecological cancer. Histol. Histopathol. 2009, 24, 1607-1615.
88. Pan, X.Y.; Wang, B.; Che, Y.C.; Weng, Z.P.; Dai, H.Y.; Peng, W. Expression of claudin-3 and claudin-4 in normal, hyperplastic, and malignant endometrial tissue. Int. J. Gynecol. Cancer 2007, 17, 233-241.
89. Santin, A.D.; Bellone, S.; Siegel, E.R.; McKenney, J.K.; Thomas, M.; Roman, J.J.; Burnett, A.; Tognon, G.; Bandiera, E.; Pecorelli, S. Overexpression of clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in uterine carcinosarcomas. Clin. Cancer Res. 2007, 13, 3339-3346.
90. Lee, J.W.; Lee, S.J.; Seo, J.; Song, S.Y.; Ahn, G.; Park, C.S.; Lee, J.H.; Kim, B.G.; Bae, D.S. Increased expressions of claudin-1 and claudin-7 during the progression of cervical neoplasia. Gynecol. Oncol. 2005, 97, 53-59.
91. Sobel, G.; Paska, C.; Szabo, I.; Kiss, A.; Kadar, A.; Schaff, Z. Increased expression of claudins in cervical squamous intraepithelial neoplasia and invasive carcinoma. Human Pathol. 2005, 36, 162-169.
92. Sobel, G.; Szabo, I.; Paska, C.; Kiss, A.; Kovalszky, I.; Kadar, A.; Paulin, F.; Schaff, Z. Changes of cell adhesion and extracellular matrix (ecm) components in cervical intraepithelial neoplasia. Pathol. Oncol. Res. 2005, 11, 26-31.
93. Honda, H.; Pazin, M.J.; Ji, H.; Wernyj, R.P.; Morin, P.J. Crucial roles of sp1 and epigenetic modifications in the regulation of the cldn4 promoter in ovarian cancer cells. J. Biol. Chem. 2006, 281, 21433-21444.
94. Kwon, M.J.; Kim, S.S.; Choi, Y.L.; Jung, H.S.; Balch, C.; Kim, S.H.; Song, Y.S.; Marquez, V.E.; Nephew, K.P.; Shin, Y.K. Derepression of cldn3 and cldn4 during ovarian tumorigenesis is associated with loss of repressive histone modifications. Carcinogenesis 2010, 31, 974-983.
95. Casagrande, F.; Cocco, E.; Bellone, S.; Richter, C.E.; Bellone, M.; Todeschini, P.; Siegel, E.; Varughese, J.; Arin-Silasi, D.; Azodi, M.; et al. Eradication of chemotherapy-resistant cd44+ human ovarian cancer stem cells in mice by intraperitoneal administration of clostridium perfringens enterotoxin. Cancer 2011, 117, 5519-5528.
96. Stewart, J.J.; White, J.T.; Yan, X.; Collins, S.; Drescher, C.W.; Urban, N.D.; Hood, L.; Lin, B. Proteins associated with cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mrna expression levels. Mol. Cell Proteomics 2006, 5, 433-443.
97. Santin, A.D.; Cane, S.; Bellone, S.; Palmieri, M.; Siegel, E.R.; Thomas, M.; Roman, J.J.; Burnett, A.; Cannon, M.J.; Pecorelli, S. Treatment of chemotherapy-resistant human ovarian cancer xenografts in c.B-17/scid mice by intraperitoneal administration of clostridium perfringens enterotoxin. Cancer Res. 2005, 65, 4334-4342.
98. Yoshida, H.; Sumi, T.; Zhi, X.; Yasui, T.; Honda, K.; Ishiko, O. Claudin-4: A potential therapeutic target in chemotherapy-resistant ovarian cancer. Anticancer Res. 2011, 31, 1271-1277.
99. Thiery, J.P.; Acloque, H.; Huang, R.Y.; Nieto, M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139, 871-890.
100. Yilmaz, M.; Christofori, G. Emt, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009, 28, 15-33.
101. Foty, R.A.; Steinberg, M.S. Cadherin-mediated cell-cell adhesion and tissue segregation in relation to malignancy. Int. J. Dev. Biol. 2004, 48, 397-409.
102. Szasz, A.M.; Nemeth, Z.; Gyorffy, B.; Micsinai, M.; Krenacs, T.; Baranyai, Z.; Harsanyi, L.; Kiss, A.; Schaff, Z.; Tokes, A.M.; et al. Identification of a claudin-4 and e-cadherin score to predict prognosis in breast cancer. Cancer Sci. 2011, 102, 2248-2254.
103. Lee, K.W.; Lee, N.K.; Kim, J.H.; Kang, M.S.; Yoo, H.Y.; Kim, H.H.; Um, S.H.; Kim, S.H. Twist1 causes the transcriptional repression of claudin-4 with prognostic significance in esophageal cancer. Biochem. Biophys. Res. Commun. 2012, 423, 454-460.
104. Ersoz, S.; Mungan, S.; Cobanoglu, U.; Turgutalp, H.; Ozoran, Y. Prognostic importance of claudin-1 and claudin-4 expression in colon carcinomas. Pathol. Res. Pract. 2011, 207, 285-289.
105. Tsutsumi, K.; Sato, N.; Tanabe, R.; Mizumoto, K.; Morimatsu, K.; Kayashima, T.; Fujita, H.; Ohuchida, K.; Ohtsuka, T.; Takahata, S.; et al. Claudin-4 expression predicts survival in pancreatic ductal adenocarcinoma. Ann. Surg. Oncol. 2012, 19, S491-S499.
106. Finch, A.; Shaw, P.; Rosen, B.; Murphy, J.; Narod, S.A.; Colgan, T.J. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 brca1 and brca2 carriers. Gynecol. Oncol. 2006, 100, 58-64.
107. Lee, Y.; Miron, A.; Drapkin, R.; Nucci, M.R.; Medeiros, F.; Saleemuddin, A.; Garber, J.; Birch, C.; Mou, H.; Gordon, R.W.; et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J. Pathol. 2007, 211, 26-35.
108. Karst, A.M.; Levanon, K.; Drapkin, R. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc. Natl. Acad. Sci. USA 2011, 108, 7547-7552.
109. Shang, X.; Lin, X.; Manorek, G.; Howell, S.B. Claudin-3 and claudin-4 regulate sensitivity to cisplatin by controlling expression of the copper and cisplatin influx transporter ctr1. Mol. Pharmacol. 2013, 83, 85-94.
110. Litkouhi, B.; Kwong, J.; Lo, C.M.; Smedley, J.G., 3rd; McClane, B.A.; Aponte, M.; Gao, Z.; Sarno, J.L.; Hinners, J.; Welch, W.R.; et al. Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of clostridium perfringens enterotoxin. Neoplasia 2007, 9, 304-314.
111. Choi, Y.L.; Kim, J.; Kwon, M.J.; Choi, J.S.; Kim, T.J.; Bae, D.S.; Koh, S.S.; In, Y.H.; Park, Y.W.; Kim, S.H.; et al. Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation. Histol. Histopathol. 2007, 22, 1185-1195.
112. Huang, Y.H.; Bao, Y.; Peng, W.; Goldberg, M.; Love, K.; Bumcrot, D.A.; Cole, G.; Langer, R.; Anderson, D.G.; Sawicki, J.A. Claudin-3 gene silencing with sirna suppresses ovarian tumor growth and metastasis. Proc. Natl. Acad. Sci. USA 2009, 106, 3426-3430.
113. Facchetti, F.; Lonardi, S.; Gentili, F.; Bercich, L.; Falchetti, M.; Tardanico, R.; Baronchelli, C.; Lucini, L.; Santin, A.; Murer, B. Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions. Virchows Archiv. 2007, 451, 669-680.
114. Rodewald, M.; Herr, D.; Duncan, W.C.; Fraser, H.M.; Hack, G.; Konrad, R.; Gagsteiger, F.; Kreienberg, R.; Wulff, C. Molecular mechanisms of ovarian hyperstimulation syndrome: Paracrine reduction of endothelial claudin 5 by hcg in vitro is associated with increased endothelial permeability. Hum. Reprod. 2009, 24, 1191-1199.
115. Dvorak, H.F.; Nagy, J.A.; Feng, D.; Brown, L.F.; Dvorak, A.M. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr. Top Microbiol. Immunol. 1999, 237, 97-132.
116. Dvorak, H.F. Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 2002, 20, 4368-4380.
117. Olson, T.A.; Mohanraj, D.; Carson, L.F.; Ramakrishnan, S. Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res. 1994, 54, 276-280.
118. Hazelton, D.; Nicosia, R.F.; Nicosia, S.V. Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy. Clin. Cancer Res. 1999, 5, 823-829.
119. Herr, D.; Sallmann, A.; Bekes, I.; Konrad, R.; Holzheu, I.; Kreienberg, R.; Wulff, C. Vegf induces ascites in ovarian cancer patients via increasing peritoneal permeability by downregulation of claudin 5. Gynecol. Oncol. 2012, 127, 210-216.
120. Turunen, M.; Talvensaari-Mattila, A.; Soini, Y.; Santala, M. Claudin-5 overexpression correlates with aggressive behavior in serous ovarian adenocarcinoma. Anticancer Res. 2009, 29, 5185-5189.
121. Wang, L.; Xue, Y.; Shen, Y.; Li, W.; Cheng, Y.; Yan, X.; Shi, W.; Wang, J.; Gong, Z.; Yang, G.; et al. Claudin 6: A novel surface marker for characterizing mouse pluripotent stem cells. Cell Res. 2012, 22, 1082-1085.
122. Turksen, K.; Troy, T.C. Claudin-6: A novel tight junction molecule is developmentally regulated in mouse embryonic epithelium. Dev. Dyn. 2001, 222, 292-300.
123. Anderson, W.J.; Zhou, Q.; Alcalde, V.; Kaneko, O.F.; Blank, L.J.; Sherwood, R.I.; Guseh, J.S.; Rajagopal, J.; Melton, D.A. Genetic targeting of the endoderm with claudin-6creer. Dev. Dyn. 2008, 237, 504-512.
124. Birks, D.K.; Kleinschmidt-DeMasters, B.K.; Donson, A.M.; Barton, V.N.; McNatt, S.A.; Foreman, N.K.; Handler, M.H. Claudin 6 is a positive marker for atypical teratoid/rhabdoid tumors. Brain Pathol. 2010, 20, 140-150.
125. Yafang, L.; Qiong, W.; Yue, R.; Xiaoming, X.; Lina, Y.; Mingzi, Z.; Ting, Z.; Yulin, L.; Chengshi, Q. Role of estrogen receptor-alpha in the regulation of claudin-6 expression in breast cancer cells. J. Breast Cancer 2011, 14, 20-27.
126. Rendon-Huerta, E.; Teresa, F.; Teresa, G.M.; Xochitl, G.S.; Georgina, A.F.; Veronica, Z.Z.; Montano, L.F. Distribution and expression pattern of claudins 6, 7, and 9 in diffuse- and intestinal-type gastric adenocarcinomas. J. Gastrointest Cancer 2010, 41, 52-59.
127. Lal-Nag, M.; Battis, M.; Santin, A.D.; Morin, P.J. Claudin-6: A novel receptor for cpe-mediated cytotoxicity in ovarian cancer. Oncogenesis 2012, 1, e33.
128. Smedley, J.G., 3rd; McClane, B.A. Fine mapping of the N-terminal cytotoxicity region of clostridium perfringens enterotoxin by site-directed mutagenesis. Infect Immun. 2004, 72, 6914-6923.
129. Kim, C.J.; Lee, J.W.; Choi, J.J.; Choi, H.Y.; Park, Y.A.; Jeon, H.K.; Sung, C.O.; Song, S.Y.; Lee, Y.Y.; Choi, C.H.; et al. High claudin-7 expression is associated with a poor response to platinum-based chemotherapy in epithelial ovarian carcinoma. Eur. J. Cancer 2011, 47, 918-925.
130. Usami, Y.; Chiba, H.; Nakayama, F.; Ueda, J.; Matsuda, Y.; Sawada, N.; Komori, T.; Ito, A.; Yokozaki, H. Reduced expression of claudin-7 correlates with invasion and metastasis in squamous cell carcinoma of the esophagus. Human Pathol. 2006, 37, 569-577.
131. Al Moustafa, A.E.; Alaoui-Jamali, M.A.; Batist, G.; Hernandez-Perez, M.; Serruya, C.; Alpert, L.; Black, M.J.; Sladek, R.; Foulkes, W.D. Identification of genes associated with head and neck carcinogenesis by cdna microarray comparison between matched primary normal epithelial and squamous carcinoma cells. Oncogene 2002, 21, 2634-2640.
132. Sheehan, G.M.; Kallakury, B.V.; Sheehan, C.E.; Fisher, H.A.; Kaufman, R.P., Jr.; Ross, J.S. Loss of claudins-1 and -7 and expression of claudins-3 and -4 correlate with prognostic variables in prostatic adenocarcinomas. Human pathology 2007, 38, 564-569.
133. Sauer, T.; Pedersen, M.K.; Ebeltoft, K.; Naess, O. Reduced expression of claudin-7 in fine needle aspirates from breast carcinomas correlate with grading and metastatic disease. Cytopathology 2005, 16, 193-198.
134. Katahira, J.; Sugiyama, H.; Inoue, N.; Horiguchi, Y.; Matsuda, M.; Sugimoto, N. Clostridium perfringens enterotoxin utilizes two structurally related membrane proteins as functional receptors in vivo. J. Biol. Chem. 1997, 272, 26652-26658.
135. Cocco, E.; Casagrande, F.; Bellone, S.; Richter, C.E.; Bellone, M.; Todeschini, P.; Holmberg, J.C.; Fu, H.H.; Montagna, M.K.; Mor, G.; et al. Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer. BMC Cancer 2010, 10, 349.
136. Kakutani, H.; Kondoh, M.; Saeki, R.; Fujii, M.; Watanabe, Y.; Mizuguchi, H.; Yagi, K. Claudin-4-targeting of diphtheria toxin fragment a using a C-terminal fragment of clostridium perfringens enterotoxin. Eur. J. Pharm. Biopharm. 2010, 75, 213-217.
137. Ebihara, C.; Kondoh, M.; Hasuike, N.; Harada, M.; Mizuguchi, H.; Horiguchi, Y.; Fujii, M.; Watanabe, Y. Preparation of a claudin-targeting molecule using a C-terminal fragment of clostridium perfringens enterotoxin. J. Pharmacol. Exp. Ther. 2006, 316, 255-260.
138. Yuan, X.; Lin, X.; Manorek, G.; Kanatani, I.; Cheung, L.H.; Rosenblum, M.G.; Howell, S.B. Recombinant cpe fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors. Mol. Cancer Ther. 2009, 8, 1906-1915.
139. Michl, P.; Buchholz, M.; Rolke, M.; Kunsch, S.; Lohr, M.; McClane, B.; Tsukita, S.; Leder, G.; Adler, G.; Gress, T.M. Claudin-4: A new target for pancreatic cancer treatment using clostridium perfringens enterotoxin. Gastroenterology 2001, 121, 678-684.
140. Long, H.; Crean, C.D.; Lee, W.H.; Cummings, O.W.; Gabig, T.G. Expression of clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium. Cancer Res. 2001, 61, 7878-7881.
141. Kominsky, S.L.; Vali, M.; Korz, D.; Gabig, T.G.; Weitzman, S.A.; Argani, P.; Sukumar, S. Clostridium perfringens enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4. Am. J. Pathol.2004, 164, 1627-1633.
142. McClane, B.A. An overview of clostridium perfringens enterotoxin. Toxicon 1996, 34, 1335-1343.
143. Kokai-Kun, J.F.; McClane, B.A. Deletion analysis of the clostridium perfringens enterotoxin. Infect Immun. 1997, 65, 1014-1022.
144. Kokai-Kun, J.F.; Benton, K.; Wieckowski, E.U.; McClane, B.A. Identification of a clostridium perfringens enterotoxin region required for large complex formation and cytotoxicity by random mutagenesis. Infect Immun. 1999, 67, 5634-5641.
145. Kokai-Kun, J.F.; McClane, B.A. Evidence that a region(s) of the clostridium perfringens enterotoxin molecule remains exposed on the external surface of the mammalian plasma membrane when the toxin is sequestered in small or large complexes. Infect Immun. 1996, 64, 1020-1025.
146. Yamamoto, A.; Uchiyama, T.; Nishikawa, R.; Fujita, T.; Muranishi, S. Effectiveness and toxicity screening of various absorption enhancers in the rat small intestine: Effects of absorption enhancers on the intestinal absorption of phenol red and the release of protein and phospholipids from the intestinal membrane. J. Pharm. Pharmacol. 1996, 48, 1285-1289.
147. Kondoh, M.; Takahashi, A.; Fujii, M.; Yagi, K.; Watanabe, Y. A novel strategy for a drug delivery system using a claudin modulator. Biol. Pharm. Bull. 2006, 29, 1783-1789.
148. Gao, Z.; Xu, X.; McClane, B.; Zeng, Q.; Litkouhi, B.; Welch, W.R.; Berkowitz, R.S.; Mok, S.C.; Garner, E.I. C-terminus of clostridium perfringens enterotoxin downregulates cldn4 and sensitizes ovarian cancer cells to taxol and carboplatin. Clin. Cancer Res. 2011, 17, 1065-1074.
149. Alberts, D.S.; Markman, M.; Armstrong, D.; Rothenberg, M.L.; Muggia, F.; Howell, S.B. Intraperitoneal therapy for stage iii ovarian cancer: A therapy whose time has come! J. Clin. Oncol. 2002, 20, 3944-3946.
150. Kominsky, S.L.; Tyler, B.; Sosnowski, J.; Brady, K.; Doucet, M.; Nell, D.; Smedley, J.G., 3rd; McClane, B.; Brem, H.; Sukumar, S. Clostridium perfringens enterotoxin as a novel-targeted therapeutic for brain metastasis. Cancer Res. 2007, 67, 7977-7982.
151. Santin, A.D.; Bellone, S.; Marizzoni, M.; Palmieri, M.; Siegel, E.R.; McKenney, J.K.; Hennings, L.; Comper, F.; Bandiera, E.; Pecorelli, S. Overexpression of claudin-3 and claudin-4 receptors in uterine serous papillary carcinoma: Novel targets for a type-specific therapy using clostridium perfringens enterotoxin (cpe). Cancer 2007, 109, 1312-1322.
152. Walther, W.; Petkov, S.; Kuvardina, O.N.; Aumann, J.; Kobelt, D.; Fichtner, I.; Lemm, M.; Piontek, J.; Blasig, I.E.; Stein, U.; et al. Novel clostridium perfringens enterotoxin suicide gene therapy for selective treatment of claudin-3- and -4-overexpressing tumors. Gene Ther. 2012, 19, 494-503.